Related Experiment Videos

Antimutagenicity of benzo[a]phenothiazines in chemically induced mutagenesis

M Tanaka1, K Wayda, J Molnár

  • 1Faculty of Medicine, Institute of Microbiology, Albert Szent-Györgyi Medical University, Szeged, Hungary.

Anticancer Research
|March 1, 1997
PubMed

Insights

Seven benzo[a]phenothiazines were screened for antimutagenicity. 6-Hydroxy-5-oxo-5H-benzo[a]phenothiazine demonstrated potent antimutagenic activity, exceeding that of chlorpromazine, suggesting potential in cancer chemoprevention.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Toxicology

Background:

  • Antimutagenicity is crucial for developing cancer chemopreventive agents.
  • Multistage carcinogenesis involves successive mutation sequences.
  • Phenothiazine derivatives are known mutagen inhibitors.

Purpose of the Study:

  • To screen the antimutagenicity of seven benzo[a]phenothiazines.
  • To compare their efficacy against chlorpromazine, a known mutagen inhibitor.
  • To identify novel compounds with potential cancer chemopreventive properties.

Main Methods:

  • Screening of seven benzo[a]phenothiazines against Salmonella typhimurium strain TA98.
  • Treatment with 4-nitro-o-phenylenediamine, a specific mutagen.
  • Comparative analysis with the antimutagenic activity of chlorpromazine.

Main Results:

  • Benzo[a]phenothiazines with methyl, oxo, or hydroxyl substituents at positions 5, 6, 9, or 10 were tested.
  • 6-Hydroxy-5-oxo-5H-benzo[a]phenothiazine reduced induced mutation by 27%.
  • This compound exhibited greater antimutagenic potency than chlorpromazine.

Conclusions:

  • 6-Hydroxy-5-oxo-5H-benzo[a]phenothiazine is a potent antimutagenic agent.
  • This finding holds significant interest for developing novel cancer chemopreventive agents.
  • Further research into benzo[a]phenothiazines could lead to effective strategies against multistage carcinogenesis.

Related Concept Videos